0.9159
3.67%
+0.0324
Durect Corp stock is currently priced at $0.9159, with a 24-hour trading volume of 33,644.
It has seen a +3.67% increased in the last 24 hours and a -28.45% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $0.8723 pivot point. If it approaches the $0.9247 resistance level, significant changes may occur.
Previous Close:
$0.8835
Open:
$0.8711
24h Volume:
33,644
Market Cap:
$28.43M
Revenue:
$9.19M
Net Income/Loss:
$-36.65M
P/E Ratio:
-0.5947
EPS:
-1.54
Net Cash Flow:
$-34.57M
1W Performance:
+0.65%
1M Performance:
-28.45%
6M Performance:
-61.35%
1Y Performance:
-78.40%
Durect Corp Stock (DRRX) Company Profile
Durect Corp Stock (DRRX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Oct-30-20 | Initiated | Chardan Capital Markets | Buy |
Oct-12-20 | Initiated | ROTH Capital | Buy |
Jul-31-20 | Initiated | Oppenheimer | Outperform |
Jan-31-20 | Initiated | B. Riley FBR | Buy |
Nov-18-19 | Resumed | Cantor Fitzgerald | Overweight |
Sep-06-19 | Initiated | Cantor Fitzgerald | Overweight |
Mar-06-18 | Upgrade | H.C. Wainwright | Neutral → Buy |
Oct-20-17 | Downgrade | H.C. Wainwright | Buy → Neutral |
Oct-20-17 | Reiterated | Laidlaw | Buy |
Oct-20-17 | Downgrade | Stifel | Buy → Hold |
Jul-12-17 | Upgrade | Stifel | Hold → Buy |
Feb-28-17 | Resumed | H.C. Wainwright | Buy |
Apr-25-16 | Initiated | Rodman & Renshaw | Buy |
May-01-15 | Reiterated | Cantor Fitzgerald | Buy |
May-01-15 | Reiterated | Stifel | Buy |
Mar-25-13 | Initiated | Stifel | Buy |
Nov-01-12 | Downgrade | C.K. Cooper | Buy → Hold |
Aug-17-12 | Initiated | C.K. Cooper | Buy |
Jun-23-09 | Initiated | Caris & Company | Buy |
Mar-26-09 | Initiated | Wedbush Morgan | Hold |
View All
Durect Corp Stock (DRRX) Latest News
Durect (DRRX) Reports Q4 Loss, Misses Revenue Estimates
Zacks Investment Research
MediWound (MDWD) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q4
Zacks Investment Research
Pacira (PCRX) Matches Q4 Earnings Estimates
Zacks Investment Research
Top 3 Health Care Stocks That Are Preparing To Pump This Month
Benzinga
Rare Stock Picks In November 2023 - From 31 Discerning Analysts
Seeking Alpha
Durect Corp Stock (DRRX) Financials Data
Durect Corp (DRRX) Revenue 2024
DRRX reported a revenue (TTM) of $9.19 million for the quarter ending September 30, 2023, a -60.48% decline year-over-year.
Durect Corp (DRRX) Net Income 2024
DRRX net income (TTM) was -$36.65 million for the quarter ending September 30, 2023, a -15.00% decrease year-over-year.
Durect Corp (DRRX) Cash Flow 2024
DRRX recorded a free cash flow (TTM) of -$34.57 million for the quarter ending September 30, 2023, a -18.87% decrease year-over-year.
Durect Corp (DRRX) Earnings per Share 2024
DRRX earnings per share (TTM) was -$1.58 for the quarter ending September 30, 2023, a -12.86% decline year-over-year.
About Durect Corp
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and drug delivery programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for use as raw materials in their products for pharmaceutical and medical devices under the LACTEL brand. Its product pipeline consists of multiple investigational drug candidates in clinical development, such as DUR-928, an endogenous, orally bioavailable small molecule that is in Phase II development stage to play a regulatory role in lipid homeostasis, inflammation, and cell survival. The company's advanced oral and injectable delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs, including REMOXY ER, an investigational extended release pain relief drug based on ORADUR technology; and POSIMIR, an investigational analgesic product intended to deliver bupivacaine to provide up to 3 days of pain relief after surgery. DURECT Corporation markets and sells its ALZET and LACTEL product lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has collaboration agreements with Sandoz AG; Indivior UK Ltd.; Santen Pharmaceutical Co., Ltd.; Zogenix, Inc.; and Pain Therapeutics, Inc. DURECT Corporation was founded in 1998 and is headquartered in Cupertino, California.
Cap:
|
Volume (24h):